Received: Feb 20, 2018 at 7:15 PM Subject: Consider a twice-weekly therapy that keeps things simple for you From: CSL Behring Team
Received: Oct 4, 2018 at 12:01 PM Subject: 1 alternative to Helixate® FS: Novoeight® (Antihemophilic Factor [Recombinant]). From: Novo Nordisk
From: ACADIA Pharmaceuticals Inc. Sent on: Jan 21, 2019 Subject line: You signed up to learn more. We’re happy to help Preheader: Please see Important Safety Information including Boxed WARNING at the bottom of this email.
Subject line: Commercial Copay Assistance Sent on: 8/23/2018 at 9 AM From: Managing LGS Pre-header: Learn about the updates to our Commercial Copay Assistance Program
Subject line: 3 important considerations regarding rFIX treatments Sent on: Aug 16, 2018 at 7AM From: Novo Nordisk Pre-header: Providing more for your patients with hemophilia B.